Warberg Asset Management’s Regentis Biomaterials RGNT Stock Holding History

Warberg Asset Management’s Portfolio RGNT Stock Details RGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,093	Closed	-$127K	–	235
2025 Q4	$127K	Buy	+19,093	New	+$131K	0.02%	134

Other funds holding RGNT

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Warberg Asset Management's RGNT Position: Q1 2026 in Review

Warberg Asset Management sold out of Regentis Biomaterials (RGNT) in Q1 2026, closing a stake of 19,093 shares — an estimated $127K sold.

Warberg Asset Management first reported a position in RGNT in Q4 2025 and held it in 1 quarter. The position peaked at $127K in Q4 2025. 3 funds tracked by Wall St. Rank hold RGNT as of Q1 2026.

Warberg Asset Management reported no remaining Regentis Biomaterials position as of Q1 2026 after selling out during the quarter.
Warberg Asset Management sold 19,093 Regentis Biomaterials shares in Q1 2026, an estimated $127K.
Warberg Asset Management first reported a position in Regentis Biomaterials in Q4 2025 and held it in 1 quarter.
Warberg Asset Management's Regentis Biomaterials position peaked at $127K in Q4 2025.
3 funds tracked by Wall St. Rank held Regentis Biomaterials as of Q1 2026.

Based on Warberg Asset Management's 13F filing for Q1 2026, filed 7 May 2026.